# Evolus

Evolus is an other based in Newport Beach, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Newport Beach, United States
- **Region:** North America
- **Address:** Newport Beach, CA, United States
- **Founded:** 2012
- **Assets under management:** Undisclosed
- **Website:** evolus.com

## Regulatory record

- **Reports private funds:** No

## About

Evolus launched in 2012 under the name Miramar Labs but reorganized and rebranded after Alphaeon Corporation acquired a major stake, ultimately spinning the entity out as a public company in 2018. David Moatazedi, who previously led U.S. aesthetics at Allergan, became CEO the same year and has since built Evolus around a single molecule: prabotulinumtoxinA, a 900 kDa botulinum toxin type A complex sourced from South Korea's Daewoong Pharmaceutical. That sourcing relationship provides the cost structure that underpins Evolus's entire competitive posture. The company's sole commercial product is Jeuveau, an injectable neurotoxin approved by the FDA in February 2019 for the temporary improvement of moderate-to-severe glabellar lines. Evolus markets Jeuveau directly to consumers and clinicians as a lower-priced, lifestyle-branded alternative to Botox, running the product through an Evolus-branded loyalty program rather than Allergan's category-leading Brilliant Distinctions platform. The firm competes in the $4 billion-plus U.S. neurotoxin aesthetic market against Allergan (Botox), Revance (Daxxify), Merz (Xeomin), and Galderma (Dysport). In 2021, Evolus settled a multi-year trade-secrets lawsuit with Allergan and Medytox by paying a $35 million upfront settlement and agreeing to a mid-single-digit royalty on U.S. Jeuveau sales through the patent cliff — a settlement the company funded via a debt raise to preserve commercial momentum (per SEC filing, 2021). Evolus is publicly listed on Nasdaq under the ticker EOLS. As of mid-2024, the company was generating approximately $250 million in annual net revenue, driven almost entirely by Jeuveau in the U.S. market. The company runs a lean operation out of Newport Beach, California; it does not operate its own manufacturing facilities and instead relies on Daewoong for supply. In July 2024, Evolus entered the European filler market through the acquisition of a dermal-filler portfolio from Symatese, adding a physical-product line alongside the neurotoxin franchise (per Evolus press release, July 2024). The company also operates an expanding digital loyalty program, Evolus Rewards, as a direct patient-retention mechanism tied to the cash-pay aesthetic business model. Evolus's structural differentiator is its pricing architecture rather than scientific novelty. Where Allergan built Botox as a physician-trust brand, Evolus built Jeuveau as a consumer-price play — the only publicly traded pure-play neurotoxin company whose entire narrative turns on the patent-expiry window for the category leader. The company's future depends on whether mid-teens volume growth in the aesthetics market can outrun price compression as competing toxins proliferate.

## Sectors

- Healthcare Services

## People

- David Moatazedi — President and Chief Executive Officer

## Questions

### Who runs investment and capital-allocation decisions at Evolus?

Evolus is a publicly traded operating company, not an investment firm. Capital allocation — including the 2021 litigation settlement, convertible-debt issuances, and the 2024 Symatese dermal-filler acquisition — is managed by CEO David Moatazedi and CFO Sandra Beaver, overseen by the board of directors. The company does not manage a portfolio of third-party investments or function as a family office.

### How does Evolus source and protect its manufacturing supply chain?

Evolus sources its botulinum toxin molecule exclusively from Daewoong Pharmaceutical in South Korea, a relationship that survived a multi-year misappropriation-of-trade-secrets lawsuit brought by Allergan and Medytox in the United States. After settling that litigation in 2021, the supply agreement remains intact, and Evolus pays a mid-single-digit royalty on Jeuveau sales through the life of the applicable patent portfolio. The company carries no in-house manufacturing capacity.

### What is Evolus's known posture on co-investments alongside external partners?

As an operating company, Evolus does not participate in co-investment structures or pooled fund vehicles. Its business-development activity, such as the 2024 Symatese asset acquisition, takes the form of direct product-line acquisitions funded by the corporate balance sheet, convertible notes, or commercial-bank debt.

## Related profiles

- [NRC Health](https://altss.com/profile/nrc-health)
- [Shoe Carnival](https://altss.com/profile/shoe-carnival-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/evolus-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology